SI
ARQT icon

Symmetry Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

Symmetry Investments’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30,000
Closed -$96.9K – 181
2023
Q4 		$96.9K Sell
30,000
-28,200
-48% -$76.7K 0.01% 192
2023
Q3 		$309K Hold
58,200
– – 0.06% 132
2023
Q2 		$555K Buy
58,200
+31,500
+118% +$350K 0.08% 111
2023
Q1 		$294K Buy
+26,700
New +$386K 0.07% 110

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Symmetry Investments's ARQT Position: Q1 2024 in Review

Symmetry Investments sold out of Arcutis Biotherapeutics (ARQT) in Q1 2024, closing a stake of 55,000 shares — an estimated $178K sold.

Symmetry Investments first reported a position in ARQT in Q1 2023 and held it in 3 quarters. The position peaked at $451K in Q3 2023. 168 funds tracked by Wall St. Rank hold ARQT as of Q1 2024.

  • Symmetry Investments reported no remaining Arcutis Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Symmetry Investments sold 55,000 Arcutis Biotherapeutics shares in Q1 2024, an estimated $178K.
  • Symmetry Investments first reported a position in Arcutis Biotherapeutics in Q1 2023 and held it in 3 quarters.
  • Symmetry Investments's Arcutis Biotherapeutics position peaked at $451K in Q3 2023.
  • 168 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2024.

Based on Symmetry Investments's 13F filing for Q1 2024, filed 10 May 2024.